Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citi, Opens 90-Day Upside CW
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $24.83 -0.52%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 22 | New: 24
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 22 | New: 24
Join SI Premium – FREE
Citi analyst Yigel Nochomovitz raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $35.00 (from $32.00) while maintaining a Buy rating.
- Opens 90-Day Upside Catalyst Watch
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Norfolk Southern (NSC) PT Raised to $358 at Evercore ISI
- Trump Says He's Close To Decision On Massive Iran Attack - Axios
- Lockheed Martin wins $67.7M in Navy, F-35 depot contracts
Create E-mail Alert Related Categories
Analyst PT Change, Trader TalkRelated Entities
Citi, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
